Nov 17, 2025 06:51AM Cybin Inc. (CYBN) PT Lowered to $55 at H.C. Wainwright

Oct 28, 2025 07:50AM Cybin Inc (CYBN) Halted, News Pending

Oct 15, 2025 07:04AM Cantor Highlights Cybin's (CYBN) CYB003’s Potential to Shift MDD Treatment

Oct 15, 2025 07:02AM Cantor Fitzgerald Reiterates Overweight Rating on Cybin Inc. (CYBN)

Sep 23, 2025 05:00PM CYBIN completes enrollment in anxiety disorder drug trial

Aug 26, 2025 07:31AM Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 19, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Cybin Inc. (CYBN)

Jul 17, 2025 07:30AM Cybin gets UK approval to start second phase 3 depression study

Jul 8, 2025 06:44AM Cybin Inc. (CYBN) PT Lowered to $70 at Canaccord Genuity

Jul 1, 2025 01:38PM Cybin Inc (CYBN) 10900 contracts of July 10 calls trade, share price up 8.3%

Jun 13, 2025 07:45AM Cybin Inc (CYBN) Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 6, 2025 06:11AM Lucid Capital Markets Starts Cybin Inc. (CYBN) at Buy

Jun 3, 2025 07:31AM Cybin Inc (CYBN) Announces Additional U.S. Patent Supporting CYB004

May 20, 2025 07:32AM Cybin Inc (CYBN) Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025 07:31AM Cybin Inc (CYBN) Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for CYB003

May 8, 2025 07:30AM Cybin Inc (CYBN) Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Apr 23, 2025 07:30AM Cybin Inc (CYBN) Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM

Feb 13, 2025 06:50AM Cybin Inc. (CYBN) PT Lowered to $150 at H.C. Wainwright

Feb 12, 2025 06:34AM Cybin Inc. (CYBN) PT Lowered to $73 at Canaccord Genuity

Jan 28, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Cybin Inc. (CYBN)

Jan 15, 2025 12:07PM Cybin Inc (CYBN) Launches Strategic Clinical Site Partnerships to Support PARADIGM

Nov 19, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Cybin Inc. (CYBN)

Nov 18, 2024 07:00AM Cybin Inc (CYBN) Reports Positive Phase 2 Data for CYB003

Nov 14, 2024 07:30AM Cybin Inc (CYBN) to Present 12-Month Phase 2 Data for CYB003

Nov 14, 2024 07:12AM Cybin Inc. (CYBN) PT Lowered to $86 at Canaccord Genuity

Oct 24, 2024 07:31AM Cybin Inc (CYBN) Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 1, 2024 07:30AM Cybin Inc (CYBN) Expands Clinical Team to Support CYB003 Phase 3 Program

Sep 23, 2024 06:33AM Cybin Inc. (CYBN) PT Lowered to $96 at Canaccord Genuity

Sep 19, 2024 07:26AM Cybin (CYBN) Announces Completion of Previously Announced Share Consolidation

Aug 13, 2024 07:30AM Cybin Inc (CYBN) Completes FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program

Jun 11, 2024 07:32AM Cybin Inc (CYBN) Appoints Atul Mahableshwarkar as SVP of Clinical Development